Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 6/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26018380 | 1.00 | SLC2A1 (0.33) | SLC2A1MAOBSIGMAR1ALDH1A1LMNA | |
| SCHEMBL23945883 | 0.99 | SLC2A1 (0.34) | SLC2A1MAOBSIGMAR1DAOMAOA | |
| SCHEMBL23945495 | 0.84 | SLC2A1 (0.35) | SLC2A1MAOBALDH1A1LMNAGAA | |
| SCHEMBL21107908 | 0.84 | SLC2A1 (0.35) | SLC2A1MAOBALDH1A1LMNAGAA | |
| SCHEMBL25727650 | 0.84 | KDM4E (0.36) | ALDH1A1MAPK1KDM4ESMN1; SMN2 | |
| SCHEMBL23695902 | 0.83 | SLC2A1 (0.33) | SLC2A1MAOBALDH1A1LMNAGAA | |
| SCHEMBL23806893 | 0.83 | SLC2A1 (0.33) | SLC2A1MAOBALDH1A1LMNAGAA | |
| SCHEMBL25725942 | 0.82 | KDM4E (0.32) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL25727661 | 0.82 | KDM4E (0.32) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL21106877 | 0.82 | SLC2A1 (0.34) | SLC2A1MAOBALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SLC2A1 4830/4885MAOB 2743/4885SIGMAR1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.